SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting

  • Axel Mescheder, CMO, to present an update on phase III, registrational trial of emactuzumab for patients suffering with TGCT (TANGENT)
  • Professor David Kerr, FRCP, to present on “Emactuzumab: Target Mediated Drug Disposition”
  • CTOS virtual Annual Meeting 10-13 November 2021

Dublin, Ireland, November 12, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces that Dr. Axel Mescheder, CMO, will be presenting plans for TANGENT at the upcoming CTOS Annual Meeting. TANGENT is a phase III multi-centre, randomized, double-blind, group comparator trial to assess the safety and efficacy of emactuzumab vs placebo in patients with TGCT. The Annual Meeting will be held virtually on 10 – 13 November 2021.

TANGENT study design is currently under review with the competent authorities.

In addition, SynOx clinical advisor, Professor David Kerr of Oxford University will also present  on the  pharmacokinetic and pharmacodynamic data generated with emactuzumab in the determination of the biologically optimal dose of emactuzumab in patients.

Axel Mescheder, Chief Medical Officer of SynOx, said: We look forward to sharing an update on the preparation of our Phase III pivotal development program TANGENT with the CTOS attendees. At SynOx we are excited to be moving towards the launch of this this clinical trial in the near future. In addition, Professor David Kerr will share further insight on the pharmacokinetic and pharmacodynamic results of the exploratory clinical trials investigating emactuzumab in TGCT patients.”